US HB3392 | 2013-2014 | 113th Congress
Status
Sponsorship: Moderate Partisan Bill (Republican 5-1)
Status: Introduced on October 30 2013 - 25% progression, died in committee
Action: 2013-11-01 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on October 30 2013 - 25% progression, died in committee
Action: 2013-11-01 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013 - Amends part D (Voluntary Prescription Drug Benefit Program) of title XVIII (Medicare) of the Social Security Act (SSA) to establish a safe pharmacy access program under which a prescription drug plan (PDP) sponsor (or a Medicare Advantage (MA) organization offering an MA-PD plan) shall have in place procedures designed to prevent fraud and abuse in the dispensing of certain controlled substances under Medicare part D. Allows a PDP sponsor to suspend payments and clean claim notifications to a pharmacy pending an investigation of a credible allegation of fraud against the pharmacy, unless the Secretary determines there is a good cause not to suspend payments. Directs the Secretary of Health and Human Services (HHS), under contracts entered into under the Medicare integrity program with Medicare drug integrity contractors (MEDICs), to authorize such MEDICs to obtain prescription and medical records directly from entities such as pharmacies, PDPs, and physicians. Requires a MEDIC to acknowledge receipt of a PDP sponsor referral of information for investigation, report back to the sponsor the investigation results within 45 days, and share them with appropriate agencies. Requires electronic transmission (e-prescribing) of prescriptions for certain covered Medicare part D controlled substances.
Title
Medicare Part D Patient Safety and Drug Abuse Prevention Act of 2013
Sponsors
| Rep. Gus Bilirakis [R-FL] | Rep. Billy Long [R-MO] | Sen. Ben Lujan [D-NM] | Rep. Harold Rogers [R-KY] |
| Rep. Dennis Ross [R-FL] | Rep. Ed Whitfield [R-KY] |
History
| Date | Chamber | Action |
|---|---|---|
| 2013-11-01 | House | Referred to the Subcommittee on Health. |
| 2013-10-30 | House | Referred to House Ways and Means |
| 2013-10-30 | House | Referred to House Energy and Commerce |
| 2013-10-30 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
Subjects
Drug safety, medical device, and laboratory regulation
Drug trafficking and controlled substances
Fraud offenses and financial crimes
Government studies and investigations
Health
Health care costs and insurance
Health information and medical records
Insurance industry and regulation
Internet and video services
Medicare
Prescription drugs
Retail and wholesale trades
Drug trafficking and controlled substances
Fraud offenses and financial crimes
Government studies and investigations
Health
Health care costs and insurance
Health information and medical records
Insurance industry and regulation
Internet and video services
Medicare
Prescription drugs
Retail and wholesale trades
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/113th-congress/house-bill/3392/all-info |
| Text | https://www.congress.gov/113/bills/hr3392/BILLS-113hr3392ih.pdf |
